From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesYarvitan
SynonymsMitratapid; R103757
Routes of
By mouth (0.5% solution)
ATCvet code
Pharmacokinetic data
Protein binding>99.9%[1]
MetabolismExtensive liver (sulfoxidation); first pass effect
Elimination half-life6.3 hours (mitratapide), up to 44.7 hours (metabolites)
ExcretionFeces (80–90%)[2]
CAS Number
PubChem CID
Chemical and physical data
Molar mass717.28 g/mol g·mol−1
3D model (JSmol)

Mitratapide is a veterinary drug for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids.[3] Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.[4]

The drug was developed by Janssen Pharmaceutica and is chemically related to the antifungal drugs such as itraconazole which were also developed by Janssen.

Mitratapide (under the brand name Yarvitan) was authorized for use in the EU by the European Medicines Agency for helping weight loss in dogs, but it has since been withdrawn from the market in the EU.[5]

See also[edit]


  1. ^ "Yarvitan 5 mg/ml Oral Solution for Dogs. Summary of Product Characteristics" (PDF). Retrieved 27 August 2016.
  2. ^ "Yarvitan (mitratapide). Scientific Discussion" (PDF). Retrieved 27 August 2016.
  3. ^ Mitratapide Archived 2012-04-05 at the Wayback Machine,
  4. ^ Dobenecker, B; De Bock, M; Engelen, M; Goossens, L; Scholz, A; Kienzle, E (2009). "Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles". Veterinary Research Communications. 33 (8): 839–47. doi:10.1007/s11259-009-9232-5. PMC 2776940. PMID 19544001.
  5. ^ German, AJ (20 October 2016). "Weight management in obese pets: the tailoring concept and how it can improve results". Acta Veterinaria Scandinavica. 58 (Suppl 1): 57. doi:10.1186/s13028-016-0238-z. PMC 5073926. PMID 27766974.